<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1665-1146</journal-id>
<journal-title><![CDATA[Boletín médico del Hospital Infantil de México]]></journal-title>
<abbrev-journal-title><![CDATA[Bol. Med. Hosp. Infant. Mex.]]></abbrev-journal-title>
<issn>1665-1146</issn>
<publisher>
<publisher-name><![CDATA[Instituto Nacional de Salud, Hospital Infantil de México Federico Gómez]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1665-11462016000600372</article-id>
<article-id pub-id-type="doi">10.1016/j.bmhimx.2016.11.004</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Antibody-mediated targeting of the transferrin receptor in cancer cells]]></article-title>
<article-title xml:lang="es"><![CDATA[Anticuerpos que reconocen el receptor de transferrina en células tumorales]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Luria-Pérez]]></surname>
<given-names><![CDATA[Rosendo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Helguera]]></surname>
<given-names><![CDATA[Gustavo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[José A.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="A01">
<institution><![CDATA[,Hospital Infantil de México Federico Gómez Unidad de Investigación en Enfermedades Oncológicas ]]></institution>
<addr-line><![CDATA[ Mexico City]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="A02">
<institution><![CDATA[,Instituto de Biología y Medicina Experimental  ]]></institution>
<addr-line><![CDATA[Ciudad Autónoma de Buenos Aires ]]></addr-line>
<country>Argentina</country>
</aff>
<aff id="A03">
<institution><![CDATA[,University of California UCLA-DOE Institute for Genomics and Proteomics Department of Chemistry and Biochemistry]]></institution>
<addr-line><![CDATA[Los Angeles California]]></addr-line>
<country>USA</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2016</year>
</pub-date>
<volume>73</volume>
<numero>6</numero>
<fpage>372</fpage>
<lpage>379</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S1665-11462016000600372&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S1665-11462016000600372&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S1665-11462016000600372&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract: Iron is essential for cell growth and is imported into cells in part through the action of transferrin (Tf), a protein that binds its receptor (TfR1 or CD71) on the surface of a cell, and then releases iron into endosomes. TfR1 is a single pass type-II transmembrane protein expressed at basal levels in most tissues. High expression of TfR1 is typically associated with rapidly proliferating cells, including various types of cancer. TfR1 is targeted by experimental therapeutics for several reasons: its cell surface accessibility, constitutive endocytosis into cells, essential role in cell growth and proliferation, and its overexpression by cancer cells. Among the therapeutic agents used to target TfR1, antibodies stand out due to their remarkable specificity and affinity. Clinical trials are being conducted to evaluate the safety and efficacy of agents targeting TfR1 in cancer patients with promising results. These observations suggest that therapies targeting TfR1 as direct therapeutics or delivery conduits remain an attractive alternative for the treatment of cancers that overexpress the receptor.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen: El hierro es esencial para el crecimiento celular. Es transportado dentro de las células con la ayuda de la transferrina (Tf), proteína que se une a su receptor (TfR1 o CD71) en la superficie celular y libera el hierro dentro de los endosomas. El TfR1 es una proteína de membrana tipo II que se sobreexpresa en muchos tejidos debido al requerimiento de las células para importar hierro unido a Tf. La sobreexpresión de TfR1 se ha asociado con células que proliferan rápidamente, incluyendo los diferentes tipos de cáncer. El TfR1 se ha empleado como blanco terapéutico por diversos motivos: su accesibilidad a la superficie celular, su capacidad de internalizarse constitutivamente en las células, su papel esencial en el crecimiento y la proliferación celular, así como por su sobreexpresión en las células tumorales proliferantes. Entre los agentes terapéuticos dirigidos contra el TfR1 destacan los anticuerpos, por su alta especificidad, estabilidad y propiedades estructurales. Se han realizado diversos ensayos clínicos para evaluar la seguridad y la eficacia de los anticuerpos que reconocen el TfR1 en pacientes con cáncer y se han obtenido resultados prometedores. Estas observaciones sugieren que las terapias con fundamento en el reconocimiento de TfR1, ya sea como terapia directa o empleados como acarreadores, representan una alternativa muy atractiva de tratamiento contra los diferentes tipos de cáncer que sobreexpresan este receptor.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[TfR1]]></kwd>
<kwd lng="es"><![CDATA[Anti-TfR1]]></kwd>
<kwd lng="es"><![CDATA[Inmunoconjugados]]></kwd>
<kwd lng="es"><![CDATA[Inmunoterapia]]></kwd>
<kwd lng="es"><![CDATA[Terapia contra el cáncer]]></kwd>
<kwd lng="en"><![CDATA[TfR1]]></kwd>
<kwd lng="en"><![CDATA[Anti-TfR1]]></kwd>
<kwd lng="en"><![CDATA[Immunoconjugate]]></kwd>
<kwd lng="en"><![CDATA[Immunotherapy]]></kwd>
<kwd lng="en"><![CDATA[Cancer therapy]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Mammalian iron metabolism]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Valerio]]></surname>
<given-names><![CDATA[L.G.]]></given-names>
</name>
</person-group>
<source><![CDATA[Toxicol Mech Methods]]></source>
<year>2007</year>
<volume>17</volume>
<page-range>497-517</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Transfer of iron from serum iron-binding protein to human reticulocytes]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jandl]]></surname>
<given-names><![CDATA[J.H.]]></given-names>
</name>
<name>
<surname><![CDATA[Inman]]></surname>
<given-names><![CDATA[J.K.]]></given-names>
</name>
<name>
<surname><![CDATA[Simmons]]></surname>
<given-names><![CDATA[R.L.]]></given-names>
</name>
<name>
<surname><![CDATA[Allen]]></surname>
<given-names><![CDATA[D.W.]]></given-names>
</name>
</person-group>
<source><![CDATA[J Clin Invest]]></source>
<year>1959</year>
<volume>38</volume>
<page-range>161-85</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[pH and the recycling of transferrin during receptor-mediated endocytosis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dautry-Varsat]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Ciechanover]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Lodish]]></surname>
<given-names><![CDATA[H.F.]]></given-names>
</name>
</person-group>
<source><![CDATA[Proc Natl Acad Sci U S A]]></source>
<year>1983</year>
<volume>80</volume>
<page-range>2258-62</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Identification of transferrin receptors in reticulocytes]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Van Bockxmeer]]></surname>
<given-names><![CDATA[F.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Morgan]]></surname>
<given-names><![CDATA[E.H.]]></given-names>
</name>
</person-group>
<source><![CDATA[Biochim Biophys Acta]]></source>
<year>1977</year>
<volume>468</volume>
<page-range>437-50</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Isolation and characterization of the transferrin receptor from human placenta]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Seligman]]></surname>
<given-names><![CDATA[P.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Schleicher]]></surname>
<given-names><![CDATA[R.B.]]></given-names>
</name>
<name>
<surname><![CDATA[Allen]]></surname>
<given-names><![CDATA[R.H.]]></given-names>
</name>
</person-group>
<source><![CDATA[J Biol Chem]]></source>
<year>1979</year>
<volume>254</volume>
<page-range>9943-6</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Identification of transferrin receptors on the surface of human cultured cells]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hamilton]]></surname>
<given-names><![CDATA[T.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Wada]]></surname>
<given-names><![CDATA[H.G.]]></given-names>
</name>
<name>
<surname><![CDATA[Sussman]]></surname>
<given-names><![CDATA[H.H.]]></given-names>
</name>
</person-group>
<source><![CDATA[Proc Natl Acad Sci U S A]]></source>
<year>1979</year>
<volume>76</volume>
<page-range>6406-10</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Molecular evolution of the transferrin receptor/glutamate carboxypeptidase II family]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lambert]]></surname>
<given-names><![CDATA[L.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Mitchell]]></surname>
<given-names><![CDATA[S.L.]]></given-names>
</name>
</person-group>
<source><![CDATA[J Mol Evol]]></source>
<year>2007</year>
<volume>64</volume>
<page-range>113-28</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The transferrin receptor and the targeted delivery of therapeutic agents against cancer]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Daniels]]></surname>
<given-names><![CDATA[T.R.]]></given-names>
</name>
<name>
<surname><![CDATA[Bernabeu]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[J.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Kozman]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Chiappetta]]></surname>
<given-names><![CDATA[D.A.]]></given-names>
</name>
</person-group>
<source><![CDATA[Biochim Biophys Acta]]></source>
<year>2012</year>
<volume>1820</volume>
<page-range>291-317</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Kinetics of internalization and recycling of transferrin and the transferrin receptor in a human hepatoma cell line. Effect of lysosomotropic agents]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ciechanover]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Schwartz]]></surname>
<given-names><![CDATA[A.L.]]></given-names>
</name>
<name>
<surname><![CDATA[Dautry-Varsat]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Lodish]]></surname>
<given-names><![CDATA[H.F.]]></given-names>
</name>
</person-group>
<source><![CDATA[J Biol Chem]]></source>
<year>1983</year>
<volume>258</volume>
<page-range>9681-9</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Regulated portals of entry into the cell]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Conner]]></surname>
<given-names><![CDATA[S.D.]]></given-names>
</name>
<name>
<surname><![CDATA[Schmid]]></surname>
<given-names><![CDATA[S.L.]]></given-names>
</name>
</person-group>
<source><![CDATA[Nature]]></source>
<year>2003</year>
<volume>422</volume>
<page-range>37-44</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Pathways and mechanisms of endocytic recycling]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Grant]]></surname>
<given-names><![CDATA[B.D.]]></given-names>
</name>
<name>
<surname><![CDATA[Donaldson]]></surname>
<given-names><![CDATA[J.G.]]></given-names>
</name>
</person-group>
<source><![CDATA[Nat Rev Mol Cell Biol]]></source>
<year>2009</year>
<volume>10</volume>
<page-range>597-608</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[A pH-dependent reversible conformational transition of the human transferrin receptor leads to self-association]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Turkewitz]]></surname>
<given-names><![CDATA[A.P.]]></given-names>
</name>
<name>
<surname><![CDATA[Schwartz]]></surname>
<given-names><![CDATA[A.L.]]></given-names>
</name>
<name>
<surname><![CDATA[Harrison]]></surname>
<given-names><![CDATA[S.C.]]></given-names>
</name>
</person-group>
<source><![CDATA[J Biol Chem]]></source>
<year>1988</year>
<volume>263</volume>
<page-range>16309-15</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Soluble transferrin receptor for the evaluation of erythropoiesis and iron status]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Beguin]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin Chim Acta]]></source>
<year>2003</year>
<volume>329</volume>
<page-range>9-22</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The role of hepatic transferrin receptor 2 in the regulation of iron homeostasis in the body]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Worthen]]></surname>
<given-names><![CDATA[C.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Enns]]></surname>
<given-names><![CDATA[C.A.]]></given-names>
</name>
</person-group>
<source><![CDATA[Front Pharmacol]]></source>
<year>2014</year>
<volume>5</volume>
<page-range>34</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Transferrin receptor 2 is frequently and highly expressed in glioblastomas]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Calzolari]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Larocca]]></surname>
<given-names><![CDATA[L.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Deaglio]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Finisquerra]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
<name>
<surname><![CDATA[Boe]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Raggi]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<source><![CDATA[Transl Oncol]]></source>
<year>2010</year>
<volume>3</volume>
<page-range>123-34</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Crystal structure of the ectodomain of human transferrin receptor]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lawrence]]></surname>
<given-names><![CDATA[C.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Ray]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Babyonyshev]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Galluser]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Borhani]]></surname>
<given-names><![CDATA[D.W.]]></given-names>
</name>
<name>
<surname><![CDATA[Harrison]]></surname>
<given-names><![CDATA[S.C.]]></given-names>
</name>
</person-group>
<source><![CDATA[Science]]></source>
<year>1999</year>
<volume>286</volume>
<page-range>779-82</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Crystal structure of the hereditary haemochromatosis protein HFE complexed with transferrin receptor]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bennett]]></surname>
<given-names><![CDATA[M.J.]]></given-names>
</name>
<name>
<surname><![CDATA[Lebron]]></surname>
<given-names><![CDATA[J.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Bjorkman]]></surname>
<given-names><![CDATA[P.J.]]></given-names>
</name>
</person-group>
<source><![CDATA[Nature]]></source>
<year>2000</year>
<volume>403</volume>
<page-range>46-53</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[How the binding of human transferrin primes the transferrin receptor potentiating iron release at endosomal pH]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Eckenroth]]></surname>
<given-names><![CDATA[B.E.]]></given-names>
</name>
<name>
<surname><![CDATA[Steere]]></surname>
<given-names><![CDATA[A.N.]]></given-names>
</name>
<name>
<surname><![CDATA[Chasteen]]></surname>
<given-names><![CDATA[N.D.]]></given-names>
</name>
<name>
<surname><![CDATA[Everse]]></surname>
<given-names><![CDATA[S.J.]]></given-names>
</name>
<name>
<surname><![CDATA[Mason]]></surname>
<given-names><![CDATA[A.B.]]></given-names>
</name>
</person-group>
<source><![CDATA[Proc Natl Acad Sci U S A]]></source>
<year>2011</year>
<volume>108</volume>
<page-range>13089-94</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Rosetta and the design of ligand binding sites]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moretti]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Bender]]></surname>
<given-names><![CDATA[B.J.]]></given-names>
</name>
<name>
<surname><![CDATA[Allison]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Meiler]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<source><![CDATA[Methods Mol Biol]]></source>
<year>2016</year>
<volume>1414</volume>
<page-range>47-62</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Transferrin receptors on human B and T lymphoblastoid cell lines]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Larrick]]></surname>
<given-names><![CDATA[J.W.]]></given-names>
</name>
<name>
<surname><![CDATA[Cresswell]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<source><![CDATA[Biochim Biophys Acta]]></source>
<year>1979</year>
<volume>583</volume>
<page-range>483-90</page-range></nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Common pathway for tumor cell uptake of gallium-67 and iron-59 via a transferrin receptor]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Larson]]></surname>
<given-names><![CDATA[S.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Rasey]]></surname>
<given-names><![CDATA[J.S.]]></given-names>
</name>
<name>
<surname><![CDATA[Allen]]></surname>
<given-names><![CDATA[D.R.]]></given-names>
</name>
<name>
<surname><![CDATA[Nelson]]></surname>
<given-names><![CDATA[N.J.]]></given-names>
</name>
<name>
<surname><![CDATA[Grunbaum]]></surname>
<given-names><![CDATA[Z.]]></given-names>
</name>
<name>
<surname><![CDATA[Harp]]></surname>
<given-names><![CDATA[G.D.]]></given-names>
</name>
</person-group>
<source><![CDATA[J Natl Cancer Inst]]></source>
<year>1980</year>
<volume>64</volume>
<page-range>41-53</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Human cell surface glycoprotein related to cell proliferation is the receptor for transferrin]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Trowbridge]]></surname>
<given-names><![CDATA[I.S.]]></given-names>
</name>
<name>
<surname><![CDATA[Omary]]></surname>
<given-names><![CDATA[M.B.]]></given-names>
</name>
</person-group>
<source><![CDATA[Proc Natl Acad Sci U S A]]></source>
<year>1981</year>
<volume>78</volume>
<page-range>3039-43</page-range></nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The iron metabolism of neoplastic cells: alterations that facilitate proliferation]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kwok]]></surname>
<given-names><![CDATA[J.C.]]></given-names>
</name>
<name>
<surname><![CDATA[Richardson]]></surname>
<given-names><![CDATA[D.R.]]></given-names>
</name>
</person-group>
<source><![CDATA[Crit Rev Oncol Hematol]]></source>
<year>2002</year>
<volume>42</volume>
<page-range>65-78</page-range></nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[A missense mutation in TFRC, encoding transferrin receptor 1, causes combined immunodeficiency]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jabara]]></surname>
<given-names><![CDATA[H.H.]]></given-names>
</name>
<name>
<surname><![CDATA[Boyden]]></surname>
<given-names><![CDATA[S.E.]]></given-names>
</name>
<name>
<surname><![CDATA[Chou]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Ramesh]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
<name>
<surname><![CDATA[Massaad]]></surname>
<given-names><![CDATA[M.J.]]></given-names>
</name>
<name>
<surname><![CDATA[Benson]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
</person-group>
<source><![CDATA[Nat Genet]]></source>
<year>2016</year>
<volume>48</volume>
<page-range>74-8</page-range></nlm-citation>
</ref>
<ref id="B25">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Transferrin receptor-1 and 2 expression in chronic lymphocytic leukemia]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smilevska]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Stamatopoulos]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Samara]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Belessi]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Tsompanakou]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Paterakis]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
</person-group>
<source><![CDATA[Leuk Res]]></source>
<year>2006</year>
<volume>30</volume>
<page-range>183-9</page-range></nlm-citation>
</ref>
<ref id="B26">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Clinical evaluation of Transferrin Receptor 1 and Transferrin Receptor 2-alpha mRNA in hematological disease]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nakashima]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Nakamaki]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Hattori]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
<name>
<surname><![CDATA[Maeda]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Saito]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Matsuda]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
</person-group>
<source><![CDATA[Showa Univ J Med Sci]]></source>
<year>2009</year>
<volume>21</volume>
<page-range>139-50</page-range></nlm-citation>
</ref>
<ref id="B27">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Daniels]]></surname>
<given-names><![CDATA[T.R.]]></given-names>
</name>
<name>
<surname><![CDATA[Delgado]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Helguera]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Penichet]]></surname>
<given-names><![CDATA[M.L.]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin Immunol]]></source>
<year>2006</year>
<volume>121</volume>
<page-range>159-76</page-range></nlm-citation>
</ref>
<ref id="B28">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The transferrin receptor part I: biology and targeting with cytotoxic antibodies for the treatment of cancer]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Daniels]]></surname>
<given-names><![CDATA[T.R.]]></given-names>
</name>
<name>
<surname><![CDATA[Delgado]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Rodriguez]]></surname>
<given-names><![CDATA[J.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Helguera]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Penichet]]></surname>
<given-names><![CDATA[M.L.]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin Immunol]]></source>
<year>2006</year>
<volume>121</volume>
<page-range>144-58</page-range></nlm-citation>
</ref>
<ref id="B29">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Anti-transferrin receptor monoclonal antibody and toxin-antibody conjugates affect growth of human tumour cells]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Trowbridge]]></surname>
<given-names><![CDATA[I.S.]]></given-names>
</name>
<name>
<surname><![CDATA[Domingo]]></surname>
<given-names><![CDATA[D.L.]]></given-names>
</name>
</person-group>
<source><![CDATA[Nature]]></source>
<year>1981</year>
<volume>294</volume>
<page-range>171-3</page-range></nlm-citation>
</ref>
<ref id="B30">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Mechanisms of growth inhibition by anti-transferrin receptor monoclonal antibodies]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Taetle]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Castagnola]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Mendelsohn]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<source><![CDATA[Cancer Res]]></source>
<year>1986</year>
<volume>46</volume>
<page-range>1759-63</page-range></nlm-citation>
</ref>
<ref id="B31">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Effects of monoclonal anti-transferrin receptor antibodies on in vitro growth of human solid tumor cells]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Taetle]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Honeysett]]></surname>
<given-names><![CDATA[J.M.]]></given-names>
</name>
</person-group>
<source><![CDATA[Cancer Res]]></source>
<year>1987</year>
<volume>47</volume>
<page-range>2040-4</page-range></nlm-citation>
</ref>
<ref id="B32">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Combinations of anti-transferrin receptor monoclonal antibodies inhibit human tumor cell growth in vitro and in vivo: evidence for synergistic antiproliferative effects]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[White]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Taetle]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Seligman]]></surname>
<given-names><![CDATA[P.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Rutherford]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Trowbridge]]></surname>
<given-names><![CDATA[I.S.]]></given-names>
</name>
</person-group>
<source><![CDATA[Cancer Res]]></source>
<year>1990</year>
<volume>50</volume>
<page-range>6295-301</page-range></nlm-citation>
</ref>
<ref id="B33">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Molecular events contributing to cell death in malignant human hematopoietic cells elicited by an IgG3-avidin fusion protein targeting the transferrin receptor]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ng]]></surname>
<given-names><![CDATA[P.P.]]></given-names>
</name>
<name>
<surname><![CDATA[Helguera]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Daniels]]></surname>
<given-names><![CDATA[T.R.]]></given-names>
</name>
<name>
<surname><![CDATA[Lomas]]></surname>
<given-names><![CDATA[S.Z.]]></given-names>
</name>
<name>
<surname><![CDATA[Rodriguez]]></surname>
<given-names><![CDATA[J.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Schiller]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
</person-group>
<source><![CDATA[Blood]]></source>
<year>2006</year>
<volume>108</volume>
<page-range>2745-54</page-range></nlm-citation>
</ref>
<ref id="B34">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[A neutralizing monoclonal antibody (mAb A24) directed against the transferrin receptor induces apoptosis of tumor T lymphocytes from ATL patients]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moura]]></surname>
<given-names><![CDATA[I.C.]]></given-names>
</name>
<name>
<surname><![CDATA[Lepelletier]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Arnulf]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[England]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Baude]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Beaumont]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<source><![CDATA[Blood]]></source>
<year>2004</year>
<volume>103</volume>
<page-range>1838-45</page-range></nlm-citation>
</ref>
<ref id="B35">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Recent advances in adult T-cell leukemia therapy: focus on a new anti-transferrin receptor monoclonal antibody]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Callens]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Moura]]></surname>
<given-names><![CDATA[I.C.]]></given-names>
</name>
<name>
<surname><![CDATA[Lepelletier]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Coulon]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Renand]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Dussiot]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<source><![CDATA[Leukemia]]></source>
<year>2008</year>
<volume>22</volume>
<page-range>42-8</page-range></nlm-citation>
</ref>
<ref id="B36">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Development of human single-chain antibodies to the transferrin receptor that effectively antagonize the growth of leukemias and lymphomas]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Crépin]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Goenaga]]></surname>
<given-names><![CDATA[A.L.]]></given-names>
</name>
<name>
<surname><![CDATA[Jullienne]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Bougherara]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Legay]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Benihoud]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
</person-group>
<source><![CDATA[Cancer Res]]></source>
<year>2010</year>
<volume>70</volume>
<page-range>5497-506</page-range></nlm-citation>
</ref>
<ref id="B37">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Friden]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
</person-group>
<source><![CDATA[Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates]]></source>
<year>1993</year>
</nlm-citation>
</ref>
<ref id="B38">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[An anti-transferrin receptor-avidin fusion protein exhibits both strong proapoptotic activity and the ability to deliver various molecules into cancer cells]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ng]]></surname>
<given-names><![CDATA[P.P.]]></given-names>
</name>
<name>
<surname><![CDATA[Dela Cruz]]></surname>
<given-names><![CDATA[J.S.]]></given-names>
</name>
<name>
<surname><![CDATA[Sorour]]></surname>
<given-names><![CDATA[D.N.]]></given-names>
</name>
<name>
<surname><![CDATA[Stinebaugh]]></surname>
<given-names><![CDATA[J.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Shin]]></surname>
<given-names><![CDATA[S.U.]]></given-names>
</name>
<name>
<surname><![CDATA[Shin]]></surname>
<given-names><![CDATA[D.S.]]></given-names>
</name>
</person-group>
<source><![CDATA[Proc Natl Acad Sci U S A]]></source>
<year>2002</year>
<volume>99</volume>
<page-range>10706-11</page-range></nlm-citation>
</ref>
<ref id="B39">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Lethal iron deprivation induced by non-neutralizing antibodies targeting transferrin receptor 1 in malignant B cells]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[J.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Luria-Pérez]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[López-Valdés]]></surname>
<given-names><![CDATA[H.E.]]></given-names>
</name>
<name>
<surname><![CDATA[Casero]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Daniels]]></surname>
<given-names><![CDATA[T.R.]]></given-names>
</name>
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<source><![CDATA[Leuk Lymphoma]]></source>
<year>2011</year>
<volume>52</volume>
<page-range>2169-78</page-range></nlm-citation>
</ref>
<ref id="B40">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Adriamycin(hydrazone)-antibody conjugates require internalization and intracellular acid hydrolysis for antitumor activity]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Braslawsky]]></surname>
<given-names><![CDATA[G.R.]]></given-names>
</name>
<name>
<surname><![CDATA[Kadow]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Knipe]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[McGoff]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Edson]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Kaneko]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
</person-group>
<source><![CDATA[Cancer Immunol Immunother]]></source>
<year>1991</year>
<volume>33</volume>
<page-range>367-74</page-range></nlm-citation>
</ref>
<ref id="B41">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Evaluation of efficacy of radioimmunotherapy with 90Y-labeled fully human anti-transferrin receptor monoclonal antibody in pancreatic cancer mouse models]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sugyo]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Tsuji]]></surname>
<given-names><![CDATA[A.B.]]></given-names>
</name>
<name>
<surname><![CDATA[Sudo]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Okada]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Koizumi]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Satoh]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
</person-group>
<source><![CDATA[PLoS One]]></source>
<year>2015</year>
<volume>10</volume>
</nlm-citation>
</ref>
<ref id="B42">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Intraventricular immunotoxin therapy for leptomeningeal neoplasia]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Laske]]></surname>
<given-names><![CDATA[D.W.]]></given-names>
</name>
<name>
<surname><![CDATA[Muraszko]]></surname>
<given-names><![CDATA[K.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Oldfield]]></surname>
<given-names><![CDATA[E.H.]]></given-names>
</name>
<name>
<surname><![CDATA[DeVroom]]></surname>
<given-names><![CDATA[H.L.]]></given-names>
</name>
<name>
<surname><![CDATA[Sung]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Dedrick]]></surname>
<given-names><![CDATA[R.L.]]></given-names>
</name>
</person-group>
<source><![CDATA[Neurosurgery]]></source>
<year>1997</year>
<volume>41</volume>
<page-range>1039-49</page-range></nlm-citation>
</ref>
<ref id="B43">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Binding specificity and internalization properties of an antibody-avidin fusion protein targeting the human transferrin receptor]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[J.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Helguera]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Daniels]]></surname>
<given-names><![CDATA[T.R.]]></given-names>
</name>
<name>
<surname><![CDATA[Neacato]]></surname>
<given-names><![CDATA[I.I.]]></given-names>
</name>
<name>
<surname><![CDATA[López-Valdés]]></surname>
<given-names><![CDATA[H.E.]]></given-names>
</name>
<name>
<surname><![CDATA[Charles]]></surname>
<given-names><![CDATA[A.C.]]></given-names>
</name>
</person-group>
<source><![CDATA[J Control Release]]></source>
<year>2007</year>
<volume>124</volume>
<page-range>35-42</page-range></nlm-citation>
</ref>
<ref id="B44">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Conjugation of an anti transferrin receptor IgG3-avidin fusion protein with biotinylated saporin results in significant enhancement of its cytotoxicity against malignant hematopoietic cells]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Daniels]]></surname>
<given-names><![CDATA[T.R.]]></given-names>
</name>
<name>
<surname><![CDATA[Ng]]></surname>
<given-names><![CDATA[P.P.]]></given-names>
</name>
<name>
<surname><![CDATA[Delgado]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Lynch]]></surname>
<given-names><![CDATA[M.R.]]></given-names>
</name>
<name>
<surname><![CDATA[Schiller]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Helguera]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
</person-group>
<source><![CDATA[Mol Cancer Ther]]></source>
<year>2007</year>
<volume>6</volume>
<page-range>2995-3008</page-range></nlm-citation>
</ref>
<ref id="B45">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Insights into the mechanism of cell death induced by saporin delivered into cancer cells by an antibody fusion protein targeting the transferrin receptor 1]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Daniels-Wells]]></surname>
<given-names><![CDATA[T.R.]]></given-names>
</name>
<name>
<surname><![CDATA[Helguera]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[J.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Leoh]]></surname>
<given-names><![CDATA[L.S.]]></given-names>
</name>
<name>
<surname><![CDATA[Erb]]></surname>
<given-names><![CDATA[M.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Diamante]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
</person-group>
<source><![CDATA[Toxicol In Vitro]]></source>
<year>2013</year>
<volume>27</volume>
<page-range>220-31</page-range></nlm-citation>
</ref>
<ref id="B46">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Antitumor activity in mice of an immunotoxin made with anti-transferrin receptor and a recombinant form of Pseudomonas exotoxin]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Batra]]></surname>
<given-names><![CDATA[J.K.]]></given-names>
</name>
<name>
<surname><![CDATA[Jinno]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Chaudhary]]></surname>
<given-names><![CDATA[V.K.]]></given-names>
</name>
<name>
<surname><![CDATA[Kondo]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Willingham]]></surname>
<given-names><![CDATA[M.C.]]></given-names>
</name>
<name>
<surname><![CDATA[FitzGerald]]></surname>
<given-names><![CDATA[D.J.]]></given-names>
</name>
</person-group>
<source><![CDATA[Proc Natl Acad Sci U S A]]></source>
<year>1989</year>
<volume>86</volume>
<page-range>8545-9</page-range></nlm-citation>
</ref>
<ref id="B47">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Efficacy of transferrin receptor-targeted immunotoxins in brain tumor cell lines and pediatric brain tumors]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martell]]></surname>
<given-names><![CDATA[L.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Agrawal]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Ross]]></surname>
<given-names><![CDATA[D.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Muraszko]]></surname>
<given-names><![CDATA[K.M.]]></given-names>
</name>
</person-group>
<source><![CDATA[Cancer Res]]></source>
<year>1993</year>
<volume>53</volume>
<page-range>1348-53</page-range></nlm-citation>
</ref>
<ref id="B48">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Single-chain immunotoxins directed at the human transferrin receptor containing Pseudomonas exotoxin A or diphtheria toxin: anti-TFR(Fv)-PE40 and DT388-anti-TFR(Fv)]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Batra]]></surname>
<given-names><![CDATA[J.K.]]></given-names>
</name>
<name>
<surname><![CDATA[Fitzgerald]]></surname>
<given-names><![CDATA[D.J.]]></given-names>
</name>
<name>
<surname><![CDATA[Chaudhary]]></surname>
<given-names><![CDATA[V.K.]]></given-names>
</name>
<name>
<surname><![CDATA[Pastan]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
</person-group>
<source><![CDATA[Mol Cell Biol]]></source>
<year>1991</year>
<volume>11</volume>
<page-range>2200-5</page-range></nlm-citation>
</ref>
<ref id="B49">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Modulation of doxorubicin resistance in a doxorubicin-resistant human leukaemia cell by an immunoliposome targeting transferring receptor]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Suzuki]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Inoue]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Hongoh]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Hashimoto]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Yamazoe]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
</person-group>
<source><![CDATA[Br J Cancer]]></source>
<year>1997</year>
<volume>76</volume>
<page-range>83-9</page-range></nlm-citation>
</ref>
<ref id="B50">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[C.C.]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[W.]]></given-names>
</name>
<name>
<surname><![CDATA[Tang]]></surname>
<given-names><![CDATA[W.H.]]></given-names>
</name>
<name>
<surname><![CDATA[Rait]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Yin]]></surname>
<given-names><![CDATA[Y.Z.]]></given-names>
</name>
</person-group>
<source><![CDATA[Mol Cancer Ther]]></source>
<year>2002</year>
<volume>1</volume>
<page-range>337-46</page-range></nlm-citation>
</ref>
<ref id="B51">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Development trends for monoclonal antibody cancer therapeutics]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reichert]]></surname>
<given-names><![CDATA[J.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Valge-Archer]]></surname>
<given-names><![CDATA[V.E.]]></given-names>
</name>
</person-group>
<source><![CDATA[Nat Rev Drug Discov]]></source>
<year>2007</year>
<volume>6</volume>
<page-range>349-56</page-range></nlm-citation>
</ref>
<ref id="B52">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Safety and efficacy in advanced solid tumors of a targeted nanocomplex carrying the p53 gene used in combination with docetaxel: a phase 1b study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pirollo]]></surname>
<given-names><![CDATA[K.F.]]></given-names>
</name>
<name>
<surname><![CDATA[Nemunaitis]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Leung]]></surname>
<given-names><![CDATA[P.K.]]></given-names>
</name>
<name>
<surname><![CDATA[Nunan]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Adams]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[E.H.]]></given-names>
</name>
</person-group>
<source><![CDATA[Mol Ther]]></source>
<year>2016</year>
<volume>24</volume>
<page-range>1697-706</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
